As previously reported, Morgan Stanley analyst David Risinger upgraded Allergan (AGN) to Overweight from Equal Weight, saying that fears about a “better Botox” from Revance (RVNC) may be overdone.

Noting that data about Revance’s botulinum toxin RT002 Phase 3 trial is expected “any day now,” Risinger said he thinks it could be difficult for Revance to demonstrate that RT002 is materially longer-lasting than Botox. While Risinger noted he is not predicting near-term major positive catalysts for Allergan, he thinks that the negatives have largely been priced in as the stock has pulled back 33% since July. The analyst keeps a $200 price target on Allergan, which closed Tuesday at $171.92.